Eris Lifesciences Receives ANVISA Approval at its Anmedabad Campus

Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, has announced that a manufacturing unit in its Anmedabad campus has received approval from ANVISA, Brazil's national health regulatory agency. This approval follows a successful inspection conducted by the agency in May 2025 and enables Eris to enter Brazil, the largest pharmaceutical market in South America. Eris, established in 2007, has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care. The company manufactures a wide range of prescription products across several dosage forms and markets these products across India through a network of ~5,000 stockists and 5,00,000+ retail pharmacies. Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY 25 revenue of INR 2,894 cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of ~ INR 4,000 crore over the last 3 years.